This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kazory, A. Articles by Ross, E. A. Search for Related Content PubMed PubMed Citation Articles by Kazory, A. Articles by Ross, E. A. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Heart Failure Kidney Diseases Related Collections Cardio-renal physiology/pathophysiology Congestive Other Treatment

(Circulation. 2008;117:975-983.)
© 2008 American Heart Association, Inc.

New Drugs and Technologies

Contemporary Trends in the Pharmacological and Extracorporeal Management of Heart Failure

A Nephrologic Perspective

Amir Kazory, MD; Edward A. Ross, MD

From the Division of Nephrology, Hypertension, and Transplantation, University of Florida, Gainesville.

Correspondence to Edward A. Ross, MD, Division of Nephrology, Hypertension, and Transplantation, University of Florida, Box 100224, 1600 SW Archer Rd, Room CG-98, Gainesville, FL 32610-0224. E-mail rossea{at}medicine.ufl.edu

Heart failure and chronic kidney disease share a number of risk factors and pathophysiological pathways. These 2 pathological processes coexist in large numbers of patients. Whereas the presence of chronic kidney disease in patients with heart failure adversely influences their survival, cardiovascular disease is the major cause of mortality in individuals with chronic kidney disease. The management of heart failure by cardiologists has recently expanded from pharmacological treatment to extracorporeal strategies; the interaction between (and concurrent use of) these approaches traditionally has been part of nephrology care and training. The purpose of this review is to explore these management strategies from a nephrologic standpoint and cover the pathophysiology of diuretic resistance, new pharmaceutical strategies to induce natriuresis or aquaresis, and the physiological basis and theoretical advantages of fluid removal by nontraditional peritoneal or hemofiltration approaches. This review also focuses on the technical features, safety, and potential risks of dedicated ultrafiltration devices that do not require dialysis staff or facilities and that are now readily available to nonnephrologists.

Key Words: diuretics • extracorporeal circulation • heart failure • natriuretic peptides • pharmacology

This article has been cited by other articles:

				J. T. Shin and G. W. Dec Ultrafiltration Should Not Replace Diuretics for the Initial Treatment of Acute Decompensated Heart Failure Circ Heart Fail, September 1, 2009; 2(5): 505 - 511. [Full Text] [PDF]

				C. T. Chan A critical look at acute decompensated heart failure from a nephrologist's perspective Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2024 - 2026. [Full Text] [PDF]

				A Kazory and E A Ross Ultrafiltration for decompensated heart failure: renal implications Heart, July 1, 2009; 95(13): 1047 - 1051. [Abstract] [Full Text] [PDF]

				A. Kazory and E. A. Ross Anemia: the point of convergence or divergence for kidney disease and heart failure? J. Am. Coll. Cardiol., February 24, 2009; 53(8): 639 - 647. [Abstract] [Full Text] [PDF]

				K. Kalantar-Zadeh, D. L. Regidor, C. P. Kovesdy, D. Van Wyck, S. Bunnapradist, T. B. Horwich, and G. C. Fonarow Fluid Retention Is Associated With Cardiovascular Mortality in Patients Undergoing Long-Term Hemodialysis Circulation, February 10, 2009; 119(5): 671 - 679. [Abstract] [Full Text] [PDF]